Structure-activity relationship and substrate-depedent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes

PLoS ONE

Volumn 3, Issue 7, 2008, Pages

  Haop, Miao ^a   Zhao, Yuqing ^b   Chen, Peizhan ^a   Huang, He ^c   Liu, Hong ^c   Jiang, Hualiang ^c   Zhang, Ruiwen ^d   Wang, Hui ^a  

^a Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^d University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 METHOXYLDAMMARANE 3BETA,12BETA,20 TRIOL; CARBAMAZEPINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DAMMANRANE 3BETA,12BETA,20,25 TETROL; FLUORESCENT DYE; GINSENG EXTRACT; GINSENOSIDE; KETOCONAZOLE; NIFEDIPINE; PROTOPANAXADIOL; PROTOPANAXATRIOL; SAPOGENIN; SAPONIN;

ARTICLE; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IC 50; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS SPECTROMETRY; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

CATALYSIS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; FLUORESCENT DYES; GENE EXPRESSION REGULATION; GINSENOSIDES; HUMANS; INHIBITORY CONCENTRATION 50; MASS SPECTROMETRY; PLANT PREPARATIONS; SOFTWARE; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

PANAX GINSENG;

EID: 49949113587     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002697     Document Type: Article

References (46)

1. Helms S (2004) Cancer prevention and therapeutics: Panax ginseng. Altern Med Rev 9: 259-274.
2. Attele AS, Wu JA, Yuan CS (1999) Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 58: 1685-1693.
3. Fugh-Berman A (2000) Herb-drug interactions. Lancet 355: 134-138.
4. Izzo AA (2005) Herb-drug interactions: an overview of the clinical evidence. Fundam Clin Pharmacol 19: 1-16.
5. Sparreboom A, Cox MC, Acharya MR, Figg WD (2004) Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 22: 2489-2503.
6. Wienkers LC, Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4: 825-833.
7. Henderson GL, Harkey MR, Gershwin ME, Hackman RM, Stern JS, et al. (1999) Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 65: PL209-214.
8. He N, Xie HG, Collins X, Edeki T, Yan Z (2006) Effects of individual ginsenosides, ginkgolides and flavonoids on CYP2C19 and CYP2D6 activity in human liver microsomes. Clin Exp Pharmacol Physiol 33: 813-815.
9. Chang TK, Chen J, Benetton SA (2002) In vitro effect of standardized ginseng extracts and individual ginsenosides on the catalytic activity of human CYP1A1, CYP1A2, and CYP1B1. Drug Metab Dispos 30: 378-384.
10. Liu Y, Zhang JW, Li W, Ma H, Sun J, et al. (2006) Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol Sci 91: 356-364.
11. Hasegawa H (2004) Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside: deglycosylation by intestinal bacteria and esterification with fatty acid. J Pharmacol Sci 95: 153-157.
12. Fuzzati N (2004) Analysis methods of ginsenosides. J Chromatogr B Analyt Technol Biomed Life Sci 812: 119-133.
13. Wang W, Zhao Y, Rayburn ER, Hill DL, Wang H, et al. (2007) In vitro anticancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng. Cancer Chemother Pharmacol 59: 589-601.
14. Zhao Y, Wang W, Han L, Rayburn ER, Hill DL, et al. (2007) Isolation, structural determination, and evaluation of the biological activity of 20(S)-25- methoxyl-dammarane-3beta, 12beta, 20-triol [20(S)-25-OCH3-PPD], a novel natural product from Panax notoginseng. Med Chem 3: 51-60.
15. de Groot MJ (2006) Designing better drugs: predicting cytochrome P450 metabolism. Drug Discov Today 11: 601-606.
16. Weaver R, Graham KS, Beattie IG, Riley RJ (2003) Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation. Drug Metab Dispos 31: 955-966.
17. Brown HS, Galetin A, Hallifax D, Houston JB (2006) Prediction of in vivo drug-drug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet 45: 1035-1050.
18. Niwa T, Shiraga T, Takagi A (2005) Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 28: 1805-1808.
19. Kim MJ, Kim H, Cha IJ, Park JS, Shon JH, et al. (2005) High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 19: 2651-2658.
20. Trubetskoy OV, Gibson JR, Marks BD (2005) Highly miniaturized formats for in vitro drug metabolism assays using vivid fluorescent substrates and recombinant human cytochrome P450 enzymes. J Biomol Screen 10: 56-66.
21. Marks BD, Thompson DV, Goossens TA, Trubetskoy OV (2004) High-throughput screening assays for the assessment of CYP2C9*1, CYP2C9*2, and CYP2C9*3 metabolism using fluorogenic Vivid substrates. J Biomol Screen 9: 439-449.
22. Marks BD, Smith RW, Braun HA, Goossens TA, Christenson M, et al. (2002) A high throughput screening assay to screen for CYP2E1 metabolism and inhibition using a fluorogenic vivid p450 substrate. Assay Drug Dev Technol 1: 73-81.
23. Marks BD, Goossens TA, Braun HA, Ozers MS, Smith RW, et al. (2003) High-throughput screening assays for CYP2B6 metabolism and inhibition using fluorogenic vivid substrates. AAPS PharmSci 5: E18.
24. Cohen LH, Remley MJ, Raunig D, Vaz AD (2003) In vitro drug interactions of cytochrome p450: an evaluation of fluorogenic to conventional substrates. Drug Metab Dispos 31: 1005-1015.
25. Trubetskoy O, Marks B, Zielinski T, Yuen MF, Raucy J (2005) A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line. Aaps J 7: E6-13.
26. Patel J, Buddha B, Dey S, Pal D, Mitra AK (2004) In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther 11: 262-277.
27. Ansede JH, Thakker DR (2004) High-throughput screening for stability and inhibitory activity of compounds toward cytochrome P450-mediated metabolism. J Pharm Sci 93: 239-255.
28. He N, Edeki T (2004) The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. Am J Ther 11: 206-212.
29. Ji HY, Lee HW, Kim HK, Kim HH, Chang SG, et al. (2004) Simultaneous determination of ginsenoside Rb(1) and Rg(1) in human plasma by liquid chromatography-mass spectrometry. J Pharm Biomed Anal 35: 207-212.
30. Wang H, Zou H, Kong L, Zhang Y, Pang H, et al. (1999) Determination of ginsenoside Rg3 in plasma by solid-phase extraction and high-performance liquid chromatography for pharmacokinetic study. J Chromatogr B Biomed Sci Appl 731: 403-409.
31. Wang RW, Newton DJ, Liu N, Atkins WM, Lu AY (2000) Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos 28: 360-366.
32. Nasrallah HA, Ketter TA, Kalali AH (2006) Carbamazepine and valproate for the treatment of bipolar disorder: a review of the literature. J Affect Disord 95: 69-78.
33. Peebles CT, McAuley JW, Roach J, Moore JL, Reeves AL (2000) Alternative Medicine Use by Patients with Epilepsy. Epilepsy Behav 1: 74-77.
34. Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, et al. (2000) Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 28: 1440-1448.
35. Racha JK, Zhao ZS, Olejnik N, Warner N, Chan R, et al. (2003) Substrate dependent inhibition profiles of fourteen drugs on CYP3A4 activity measured by a high throughput LCMS/MS method with four probe drugs, midazolam, testosterone, nifedipine and terfenadine. Drug Metab Pharmacokinet 18: 128-138.
36. Anger DL, Petre MA, Crankshaw DJ (2005) Heteroactivation of cytochrome P450 1A1 by teas and tea polyphenols. Br J Pharmacol 145: 926-933.
37. Nakamura H, Nakasa H, Ishii I, Ariyoshi N, Igarashi T, et al. (2002) Effects of endogenous steroids on CYP3A4-mediated drug metabolism by human liver microsomes. Drug Metab Dispos 30: 534-540.
38. Nakamura H, Torimoto N, Ishii I, Ariyoshi N, Nakasa H, et al. (2003) CYP3A4 and CYP3A7-mediated carbamazepine 10,11-epoxidation are activated by differential endogenous steroids. Drug Metab Dispos 31: 432-438.
39. Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, et al. (2004) The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J Biol Chem 279: 38091-38094.
40. Hosea NA, Miller GP, Guengerich FP (2000) Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry 39: 5929-5939.
41. Roberts AG, Atkins WM (2007) Energetics of heterotropic cooperativity between alpha-naphthoflavone and testosterone binding to CYP3A4. Arch Biochem Biophys 463: 89-101.
42. Cameron MD, Wen B, Allen KE, Roberts AG, Schuman JT, et al. (2005) Cooperative binding of midazolam with testosterone and alpha-naphthoflavone within the CYP3A4 active site: a NMR T1 paramagnetic relaxation study. Biochemistry 44: 14143-14151.
43. Lu P, Lin Y, Rodrigues AD, Rushmore TH, Baillie TA, et al. (2001) Testosterone, 7-benzyloxyquinoline, and 7-benzyloxy-4-trifluoromethyl-coumarin bind to different domains within the active site of cytochrome P450 3A4. Drug Metab Dispos 29: 1473-1479.
44. Torimoto N, Ishii I, Hata M, Nakamura H, Imada H, et al. (2003) Direct interaction between substrates and endogenous steroids in the active site may change the activity of cytochrome P450 3A4. Biochemistry 42: 15068-15077.
45. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, et al. (2004) Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 57: 592-599.
46. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, et al. (2002) Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 72: 276-287.